ORCL stock drops
Guggenheim has kept its price target for Oracle shares at $400, maintaining a 'Buy' recommendation. This suggests an upside potential of almost 100% from the closing price on Wednesday.
Guggenheim stated that the findings suggest a reduced focus on a small number of customers and increased confidence in Oracle's growth prospects as new resources become available. Bernstein has adjusted Oracle's price target to $325, up from $319, while maintaining an 'Outperform' rating, indicating that the company progresses towards its FY30 objectives without significant setbacks. The firm observed that despite the stock's decline post-earnings, investor concerns seem to revolve around Oracle's higher capital expenditure plans and the planned capital raise for FY27. Oracle Corp. (ORCL) shares are declining despite the company's fourth-quarter results exceeding analyst expectations, but Wall Street analysts remain unconcerned by the market reaction.
TheFly reported that Guggenheim advised investors to "aggressively" purchase Oracle shares following its strong quarterly performance.
Oracle shares dropped nearly 10% in pre-market trading on Thursday and were among the most discussed stocks on Stocktwits at the time of reporting.
Wall Street is perplexed but remains unfazed by the ORCL selloff
Guggenheim has upheld its price target for Oracle shares at $400, maintaining a 'Buy' recommendation. This suggests a potential increase of nearly 100% from Wednesday’s closing price. In its report, the firm noted there is no obvious justification for the decline in Oracle shares following the earnings announcement.
Guggenheim expressed optimism about Oracle's future, pointing to its first-quarter revenue guidance that exceeded expectations. The firm also emphasized an $85 billion rise in remaining performance obligations, reaching $638 billion, spurred in part by four major customers, each with contracts exceeding $8 billion.
According to Guggenheim, these outcomes indicate reduced customer concentration and boost confidence in Oracle's growth outlook as new capacities emerge.
Meanwhile, Bernstein increased its price target for Oracle to $325 from $319 and retained an 'Outperform' rating. It commented that the company is effectively progressing towards its fiscal year 2030 goals without significant issues.
While the stock's post-earnings dip raised investor concerns, Bernstein attributed these to Oracle's high capital expenditure plans and the anticipated fiscal year 2027 capital raise rather than the quarterly performance itself, acknowledging that this might not convince skeptics in the short term.
Analysts Suggest ORCL Will Continue to Spark Debate
Analysts at Piper Sandler suggest that Oracle remains a topic of discussion among investors, even after the company exceeded expectations in Q4 and saw a rise in its remaining performance obligations (RPOs). The firm is optimistic about Oracle's AI-driven cloud expansion and believes the FY27 revenue target is within reach. They also express increased confidence in management's capacity to maintain margins despite rising costs.
Jim Cramer pointed out on X that Oracle's reported backlog was substantial, but mentioned that the company will need to increase spending. He noted that although they may need to make workforce adjustments, the funding requirements aren't overwhelming.
Meanwhile, Citi described Oracle's Q4 report as mixed. Although results surpassed expectations, the fiscal 2027 earnings outlook is affected by pressure on gross margins. Nonetheless, the firm sees more positives than negatives, praises Oracle's financial discipline, and maintained their 'Buy' rating with a $330 price target.
Oracle highlights the growing demand for its cloud infrastructure as a key driver for revenue growth and its reputation for reliability
Oracle credited the increased demand for cloud infrastructure as a key factor driving its RPO and revenue growth in the fourth quarter. The company also revealed plans to introduce an AI-enhanced version of its Cerner patient care system, which is anticipated to significantly boost Oracle Health's growth to double digits by fiscal 2027. Oracle envisions AI as a transformative force in healthcare, promising improvements in patient outcomes, cost reduction, acceleration in drug development, and more efficient clinical trials and regulatory processes.
In terms of financial performance, Oracle reported a Q4 earnings per share (EPS) of $2.11 on a revenue of $19.2 billion, surpassing Wall Street's expectation of an EPS of $1.96 on $19.1 billion in revenue, according to data from Fiscal.ai.
As for investor sentiment, retail traders on Stocktwits exhibited an 'extremely bullish' attitude towards Oracle stock, with message activity reaching 'extremely high' levels at the time of reporting.